Orion (ORNBV.HE) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $65M

Market Cap: $11.5BFounded: 1990Employees: 3300-3500HQ: London, United Kingdom

Sector Ranking#106 in Small Molecule Drugs #34 in Diagnostics & Precision Medicine

Overview

Orion Corporation is a publicly traded, fully integrated pharmaceutical company with a 100+ year legacy, headquartered in Espoo, Finland. Its strategy is built on deep therapeutic expertise in oncology and pain, a vertically integrated model encompassing API manufacturing, and a global commercial presence in ~100 countries. The company is advancing a promising clinical pipeline, including the Phase 2 TEAD inhibitor ODM-212, while generating stable revenue from its established portfolio and contract manufacturing operations.

OncologyPainNeurological DiseasesRespiratory DiseasesWomen’s Health

Technology Platform

Integrated small molecule drug discovery and development expertise, with a vertically integrated platform that includes proprietary Active Pharmaceutical Ingredient (API) manufacturing capabilities and a collaborative research ecosystem (Veturi).

Funding History

2

Total raised:$65M

Series A$55MF-Prime CapitalOct 15, 2021

Seed$10MUndisclosedMar 15, 2020

Opportunities

The Phase 2 development of ODM-212 in niche oncology indications represents a near-term value inflection point.

The growing external demand for complex API manufacturing provides a scalable, high-margin revenue stream alongside the core therapeutics business.

Risk Factors

Clinical and regulatory risk is concentrated on the lead innovative asset, ODM-212.

The company faces ongoing pricing pressure and generic competition for its established product portfolio, alongside geopolitical and supply chain vulnerabilities inherent to global operations.

Competitive Landscape

Competes with large pharma and biotechs in oncology/pain R&D, and with generic companies and CDMOs in its established product and API businesses. Differentiation stems from vertical integration, focused therapeutic expertise, and a novel mechanism for its lead asset.